In silico analysis: Fulleropyrrolidine derivatives against HIV-PR mutants and SARS-CoV-2 Mpro

Abstract

Approximately 37.9 million people living with HIV (PLWH) are at risk of severe consequences from COVID-19. Urgent development of tailored treatments for PLWH, who have historically been excluded from vaccine trials, is crucial. The present study introduces some modified fulleropyrrolidine derivatives with chalcogen atoms (O, S, or Se) and hydroxymethylcarbonyl (HMC) groups to target 11 single and double HIV-1 protease (HIV-PR) mutations and the main protease of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 Mpro). The inhibitory activities of these derivatives are computationally examined through molecular docking, molecular dynamic simulations for 200 ns, and Lipinski’s rule of five (RO5). Fourier-transform infrared spectroscopy spectra and thermodynamic properties are calculated and analyzed using Density Functional Theory B88-PW91 method. The results indicate that the suggested O-compounds obey three parameters of the RO5 and HMC forms hydrogen bonds with studied viral proteases. Compounds with O and S additives display a high binding affinity with negative binding energy values for HIV-PR mutations (A71V-I84V, V77I-I84V, and I84V-L90M) and SARS-CoV-2 Mpro. The compounds with S and Se additives shift to lower frequencies of the major vibrational bands. Specifically, compound 1, with two oxygen additives, emerges as the most effective in inhibiting both HIV-PR mutations and SARS-CoV-2 Mpro.

Keywords

• covid-19
• fulleropyrrolidine
• ftir
• hiv-1 protease mutants
• sars-cov-2 mpro inhibitors
• 92c05
• 92c45
• 92c75